Share This Article:

Detection of Estrogen Responsive Breast Cancer Circulating Tumor Cells: Assay Development for Anti-Hormone Therapy Resistance

Abstract Full-Text HTML XML Download Download as PDF (Size:361KB) PP. 773-782
DOI: 10.4236/jct.2015.69085    3,054 Downloads   3,650 Views  

ABSTRACT

Recent clinical trials with histone deacetylase inhibitors (HDACi) have shown increased progression free survival by re-sensitizing resistant estrogen receptor positive (ER+) breast cancer cells to hormone suppressive therapies (HT). However, these trials lacked a sensitive, specific assay to identify and monitor HDACi/HT sensitive or resistant tumors. We tested detection of ER expression and histone acetylation of chromatin at the growth regulation by estrogen in breast cancer 1 (GREB1) gene, an estrogen-responsive gene involved in ER expression, in circulating tumor cell (CTC) as potential candidate assays for HDACi/HT sensitivity. ER+ and ER- CTC were detected and isolated from breast cancer patient peripheral blood by high speed fluorescence activated cell sorting (FACS) for use in mRNA analysis and anti-acetylated histone-mediated Chromatin Immunoprecipitation (ChIP). cDNA from mRNA and DNA extracted from the ChIP isolates were quantified by real-time PCR for GREB1. CTC isolates from patients who had an ER+ breast cancer primary contained both ER+ and ER- cells. More ER+ than ER- CTC was found in HT sensitive patients compared to HT resistant patients (p = 0.0559). GREB1 was found in acetylated histone chromatin from both ER+ and ER- CTC. The number of ER+ and ER- CTC found in peripheral blood appears to parallel patient outcomes as to their sensitivity to HT. Acetylated histone analysis can detect chromatin containing GREB1 in CTC, suggesting it may be useful as a more specific measure of HDACi effects on breast tumor cells. A larger, longitudinal data set following patients through HT/HDACi trials is needed to confirm these observations and their development for clinical use.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Litherland, S. , Barr, L. , Reynolds, R. , Griffith, E. , Sause, R. , Encarnacion, T. , Almodovar, A. , Zhu, X. , Dickstein, S. , Shao, Y. , Fanaian, N. and Decker, D. (2015) Detection of Estrogen Responsive Breast Cancer Circulating Tumor Cells: Assay Development for Anti-Hormone Therapy Resistance. Journal of Cancer Therapy, 6, 773-782. doi: 10.4236/jct.2015.69085.

References

[1] Kohler, B.A., Sherman, R.L., Howlader, N., Jemal, A., Ryerson, A.B., Henry, K.A., Boscoe, F.P., Cronin, K.A., Lake, A., Noone, A.-M., Henley, S.J., Eherman, C.R., Anderson, R.N. and Penberthy, L. (2015) Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. Journal of the National Cancer Institute, 100, 1672-1694.
[2] Wang, N., Shi, L., Li, H., Hu, Y., Du, W., Liu, W., Zheng, J., Huang, S. and Qu, X. (2012) Detection of Circulating Tumor Cells and Tumor Stem Cells in Patients with Breast Cancer by Using Flow Cytometry. Tumor Biology, 33, 561-569.
http://dx.doi.org/10.1007/s13277-011-0303-1
[3] Renoir, J.-M. (2012) Review: Estradiol Receptors in Breast Cancer Cells: Associated Co-Factors as Targets for New Therapeutic Approaches. Steriods, 77, 1249-1261.
http://dx.doi.org/10.1016/j.steroids.2012.07.019
[4] Iyer, V., Klebba, I., McCready, J., Arendt, L.M., Betancur-Boissel, M., Wu, M.-F., Zhang, X., Lewis, M.T. and Kuperwasser, C. (2012) Estrogen Promotes ER-Negative Tumor Growth and Angiogenesis through Mobilization of Bone Marrow-Derived Monocytes. Cancer Research, 72, 2705-2713.
http://dx.doi.org/10.1158/0008-5472.CAN-11-3287
[5] Aktas, B., Muller, V., Tewes, M., Zeitz, J., Kasimir-Bauer, S., Loehberg, C.R., Rack, B., Schneeweiss, A. and Fehm, T. (2011) Comparison of Estrogen and Progesterone Receptor Status of Circulating Tumor Cells and the Primary Tumor in Metastatic Breast Cancer Patients. Gynecologic Oncology, 122, 356-360.
http://dx.doi.org/10.1016/j.ygyno.2011.04.039
[6] Matrone, M.A., Whipple, R.A., Balzer, E.M. and Martin, S.S. (2010) Microtentacles tip the Balance of Cytoskeletal Forces in Circulating Tumor Cells. Cancer Research, 70, 7737-7741.
http://dx.doi.org/10.1158/0008-5472.CAN-10-1569
[7] Dong, X., Alpaugh, R.K. and Cristofanilli, M. (2012) Circulating Tumor Cells (CTCs) in Breast Cancer: A Diagnostic Tool for Prognosis and Molecular Analysis. Chinese Journal of Cancer Research, 24, 388-398.
http://dx.doi.org/10.1007/s11670-012-0279-4
[8] Gioradano, A., Egleston, B.L., Hajage, D., Bland, J., Hortobagyl, G.N., Reuben, J.M., Pierga, J.Y., Cristofanilli, M. and Bidard, F.C. (2013) Establishment and Validation of Circulating Tumor Cell-Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients. Clinical Cancer Research, 19, 1596-1602.
[9] Sun, Y.-F., Yang, X.-R., Zhou, J., Qiu, S.-J., Fan, J. and Xu, Y. (2011) Circulating Tumor Cells: Advances in Detection Methods, Biological Issues and Clinical Relevance. Journal of Cancer Research and Clinical Oncology, 137, 1151-1173.
http://dx.doi.org/10.1007/s00432-011-0988-y
[10] Pierga, J.-Y., Hajage, D., Bachelot, T., Delaloge, S., Brain, E., Compone, M., Dieras, V., Rolland, E., Mignot, L., Mthlot, C. and Bidard, F.-C. (2012) High Independent Prognostic and Predictive Value of Circulating Tumor Cells Compared with Serum Tumor Markers in a Large Prospective Trial in First-Line Chemotherapy for Metastatic Breast Cancer Patients. Annals of Oncology, 23, 618-624.
http://dx.doi.org/10.1093/annonc/mdr263
[11] Riethdorf, S., Fritsche, H., Muller, V., Rau, T., Schindbeck, C., Rack, B., Janni, W., Coith, C., Beck, K., Janicke, F., Jackson, S., Gomet, T., Cristofanilli, M. and Pantel, K. (2007) Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System. Clinical Cancer Research, 13, 920-928.
http://dx.doi.org/10.1158/1078-0432.CCR-06-1695
[12] Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Matera, J., Miller, M.C., Reuben, J.M., Doyle, G.V., Allard, W.J., Terstappen, L.W.M.M. and Hayes, D.F. (2004) Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. New England Journal of Medicine, 351, 781-791.
http://dx.doi.org/10.1056/NEJMoa040766
[13] Cristofanilli, M., Hayes, D.F., Budd, G.T., Ellis, J.M., Stopeck, A., Reuben, J.M., Doyle, G.V., Matera, J., Allard, W.J., Miller, M.C., Fritsche, H.A., Hortobagyl, G.N. and Terstappen, L.W.M.M. (2005) Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer. Journal of Clinical Oncology, 23, 1420-1430.
http://dx.doi.org/10.1200/JCO.2005.08.140
[14] Pantel, K. (2009) Pathology: Are Circulating Tumor Cells Predictive of Overall Survival? Nature Reviews Clinical Oncology, 6, 190-191.
http://dx.doi.org/10.1038/nrclinonc.2009.23
[15] Williams, C. and Lin, C-Y. (2013) Oestrogen Receptors in Breast Cancer: Basic Mechanisms and Clinical Implications. Ecancermedicalscience, 7, 370-382.
[16] Munster, P.N., Thurn, K.T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M. and Minton, S.E. (2011) A Phase II Study of the Histone Deacetylase Inhibitor Vorinstat Combined with Tamoxifen for the Treatment of Patients with Hormone Therapy-Resistant Breast Cancer. British Journal of Cancer, 104, 1828-1835.
http://dx.doi.org/10.1038/bjc.2011.156
[17] Shen, C., Huang, Y., Liu, Y., Wang, G., Zhao, Y., Wang, Z., Ten, M., Wang, Y., Flockhart, D.A., Skaar, T.C., Yan, P., Nephew, K.P., Huang, T.H.M. and Li, L. (2011) A Modulated Empirical Bayes Model for Identifying Topological and Temporal Estrogen Receptor Alpha Regulatory Networks in Breast Cancer. BMC Systems Biology, 5, 67-83.
http://dx.doi.org/10.1186/1752-0509-5-67
[18] Kubo, M., Kanaya, N., Petrossian, K., Ye, J., Warden, C., Liu, Z., Nishimura, R., Osako, T., Okido, M., Shimada, K., Takahashi, M., Chu, P., Yuan, Y.-C. and Chen, S. (2013) Inhibition of the Proliferation of Acquired Aromatase Inhibitor-Resistant Breast Cancer Cells by Histone Deacetylase Inhibitor LBH589 (Panobinostat). Breast Cancer Research and Treatment, 137, 93-107.
http://dx.doi.org/10.1007/s10549-012-2332-x
[19] Rae, J.M., Johnson, M.D., Scheys, J.O., Cordero, K.E., Larios, J.M. and Lippman, M.E. (2005) GREB1 Is Critical Regulator of Hormone Dependent Breast Cancer Growth. Breast Cancer Research and Treatment, 92, 141-149.
[20] Mohammed, H., D’Santos, C., Serandour, A.A., Ali, H.R., Brown, G.D., Atkins, A., Rueda, O.M., Holmes, K.A., Theodorou, V., Robinson, J.L.L., Zwart, W., Saadi, A., Ross-Innes, C.A., Chin, S.-F., Menon, S., Stingl, J., Palmieri, C., Caldas, C. and Carroll, J.S. (2013) Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory Factor. Cell Reports, 3, 342-349.
http://dx.doi.org/10.1016/j.celrep.2013.01.010
[21] Meng, Q., Chen, X., Sun, L., Zhao, C., Sui, G. and Cai, L. (2011) Carbamazepine Promotes Her-2 Protein Degradation in Breast Cancer Cells by Modulating HDAC6 Activity and Acetylation. Molecular and Cellular Biochemistry, 348, 165-171.
http://dx.doi.org/10.1007/s11010-010-0651-y
[22] Yardley, D.A., Ismail-Khan, R.R., Melichar, B., Lichinitser, M., Munster, P.N., Klein, P.M., Cruickshank, S., Miller, K.D., Lee, M.J. and Trepel, J.B. (2013) Randomized Phase II, Double-blind, Placebo-Controlled Study of Exemestane with or without Entinostat in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment with a Nonsteroidal Aromatase Inhibitor. Journal of Clinical Oncology, 31, 2128-2135.
http://dx.doi.org/10.1200/JCO.2012.43.7251
[23] Liu, L., Li, Y. and Tollefsbol, T.O. (2008) Gene-Environment Interactions and Epigenetic Basis of Human Diseases. Current Issues in Molecular Biology, 10, 25-36.
[24] Spassieva, S. and Bieberich, E. (2011) The Gut-to-Breast Connection—Interdependence of Sterols and Sphingolipids in Multidrug Resistance and Breast Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 11, 882-890.
http://dx.doi.org/10.2174/187152011797655168
[25] Ogretmen, B. and Hannun, Y.A. (2004) Biologically Active Sphingolipids in Cancer Pathogenesis and Treatment. Nature Reviews Cancer, 4, 604-616.
http://dx.doi.org/10.1038/nrc1411
[26] Bieberich, E. (2004) Integration of Glycosphingolipid Metabolism and Cell-Fate Decisions in Cancer and Stem Cells: Review and Hypothesis. Glycoconjugate Journal, 21, 315-327.
http://dx.doi.org/10.1023/B:GLYC.0000046274.35732.47
[27] Apostolou, P., Toloudi, M., Chatziioannou, M., Ioannou, E. and Papasotiriou, I. (2012) Cancer Stem Cells Stemness Transcription Factors Expression Correlates with Breast Cancer Disease Stage. Current Stem Cell Research & Therapy, 7, 415-419.
http://dx.doi.org/10.2174/157488812804484639
[28] Kim, M.Y., Oskarsson, T., Acharyya, S., Nguyen, D.X., Zhang, X.H., Norton, L. and Massague, J. (2009) Tumor Self-Seeding by Circulating Cancer Cells. Cell, 139, 1315-1326.
http://dx.doi.org/10.1016/j.cell.2009.11.025
[29] Cristofanilli, M., Broglio, K.R., Guarneri, V., Jackson, S., Fritsche, H.A., Islam, R., Dawood, S., Reuben, J.M., Kau, S.W., Lara, J.M., Krishnamurthy, S., Ueno, N.T., Hortobagyi, G.N. and Valero, V. (2007) Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging beyond Tumor Burden. Clinical Breast Cancer, 7, 471-479.
http://dx.doi.org/10.3816/CBC.2007.n.004
[30] Garrigan, E., Belkin, N.S., Alexander, J.J., Han, Z., Seydel, F., Carter, J., Atkinson, M., Wasserfall, C., Clare-Salzler, M.J., Amick, M.A. and Litherland, S.A. (2013) Persistent STAT5 Phosphorylation and Epigenetic Dysregulation of GM-CSF and PGS2/COX2 Expression in Type 1 Diabetic Human Monocytes. PLoS ONE, 8, e76919.
http://dx.doi.org/10.1371/journal.pone.0076919
[31] Nelson, J.D., Denisenko, O. and Bomsztyk, K. (2006) Protocol for the Fast Chromatin Immunoprecipitation (ChIP) Method. Nature Protocols, 1, 180-185.
http://dx.doi.org/10.1038/nprot.2006.27
[32] Inman, S. (2013) Breakthrough Designation Granted to Entinostat for Advanced Breast Cancer. OncLive.
www.onclive.com
[33] Hait, N.C., Allegood, J., Maceyka, M., Strub, G.M., Harikumar, K.B., Singh, S.K., Luo, C., Marmorstein, R., Kordula, T., Milstien, S. and Spiegel, S. (2009) Regulation of Histone Acetylation in the Nucleus by Sphingosine-1-Phosphate. Science, 325, 1254-1257.
http://dx.doi.org/10.1126/science.1176709
[34] Yardley, D.A., Noguchi, S., Pritchard, K.I., Burris III, H.A., Baselga, J., Gnant, M., Hortobagyi, G.N., Campone, M., Pistilli, B., Piccart, M., Melichar, B., Petrakova, K., Arena, F.P., Erdkamp, F., Harb, W.A., Feng, W., Cahana, A., Taran, T., Lebwohl, D. and Rugo, H.S. (2013) Everolimus plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Advances in Therapy, 30, 870-884.
http://dx.doi.org/10.1007/s12325-013-0060-1
[35] Chia, S., Gradishar, W., Mauriac, L., Bines, J., Amant, F., Federico, M., Fein, L., Romieu, G., Buzdar, A., Robertson, J.F., Brufsky, A., Possinger, K., Rennie, P., Sapunar, F., Lowe, E. and Piccart, M. (2008) Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared with Exemestane after Prior Nonsteroidal Aromatase Inhibitor Therapy in Post-Menopausal Women with Hormone Receptor-Positive Advanced Breast Cancer: Results for EFECT. Journal of Clinical Oncology, 26, 1664-1670.
http://dx.doi.org/10.1200/JCO.2007.13.5822
[36] NCI (2013) FDA Approval for Vorinostat. Cancer Drug Information. Cancer Topics.
www.cancer.gov
[37] Celgene Biopharmaceutical Press Release (2011) FDA Grants Accelerated Approval of ISTODAX? As Treatment for Patients with Peripheral T-Cell Lymphoma Who Have Received at Least One Prior Therapy. Celgene. Ir.celgene.com. Published Online. 16 June 2011.
[38] Campbell, R.M. and Tummino, P.J. (2014) Cancer Epigenetics Drug Discovery and Development: The Challenge of Hitting the Mark. Journal of Clinical Investigation, 124, 64-69.
http://dx.doi.org/10.1172/JCI71605

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.